DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.

Cancer Letters
Dotan MoskovichOsnat Ashur-Fabian

Abstract

High grade serous ovarian cancer (HGSOC) is the most lethal gynecologic malignancy with a need for better understanding the disease pathogenesis. The biologically active thyroid hormone, T3, is considered a tumor suppressor by promoting cell differentiation and mitochondrial respiration. Tumors evolved a strategy to avoid these anticancer actions by expressing the T3 catabolizing enzyme, Deiodinase type 3 (DIO3). This stimulates cancer proliferation and aerobic glycolysis (Warburg effect). We identified DIO3 expression in HGSOC cell lines, tumor tissues from mice and human patients, fallopian tube (FT) premalignant lesion and secretory cells of normal FT, considered the disease site-of-origin. Stable DIO3 knockdown (DIO3-KD) in HGSOC cells led to increased T3 bioavailability and demonstrated induced apoptosis and attenuated proliferation, migration, colony formation, oncogenic signaling, Warburg effect and tumor growth in mice. Proteomics analysis further indicated alterations in an array of cancer-relevant proteins, the majority of which are involved in tumor suppression and metabolism. Collectively this study establishes the functional role of DIO3 in facilitating tumorigenesis and metabolic reprogramming, and proposes this e...Continue Reading

References

Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·Y ChenW H Lee
Feb 15, 2003·Endocrinology·Cyntia Curcio-MorelliAntonio C Bianco
Jun 5, 2003·The Journal of Clinical Investigation·Bianca FriedrichsKlaudia Brix
Jul 13, 2006·The Journal of Biological Chemistry·Jörg Weiske, Otmar Huber
Aug 28, 2007·Proceedings of the National Academy of Sciences of the United States of America·Monica DenticeDomenico Salvatore
Mar 22, 2008·Molecular Endocrinology·G D Vivek SagarAntonio C Bianco
May 23, 2009·Science·Matthew G Vander HeidenCraig B Thompson
Jan 7, 2010·Endocrine Reviews·Sheue-Yann ChengPaul J Davis
Dec 30, 2010·Proceedings of the National Academy of Sciences of the United States of America·Francesco AcquatiRoberto Taramelli
Aug 9, 2011·Molecular Cancer Research : MCR·Keren CohenOsnat Ashur-Fabian
Aug 30, 2011·Journal of Inherited Metabolic Disease·An I JonckheereRichard J T Rodenburg
Oct 13, 2011·The American Journal of Surgical Pathology·Kala VisvanathanRobert J Kurman
Mar 24, 2012·Cancer Cell·Patrick S Ward, Craig B Thompson
Jul 10, 2012·Gastroenterology·Monica DenticeDomenico Salvatore
Sep 1, 2012·Nature Protocols·Alison M Karst, Ronny Drapkin
Jul 11, 2013·Nature Communications·Silvia DomckeNikolaus Schultz
Apr 29, 2014·Lancet·Gordon C JaysonJonathan A Ledermann
Jul 9, 2014·Proceedings of the National Academy of Sciences of the United States of America·Ulrich SchweizerClemens Steegborn
Oct 22, 2014·Molecular Medicine Reports·Luosheng ZhangXingwang Gao
Jan 8, 2015·Frontiers in Endocrinology·Domenico CiavardelliVeronica Vella
Mar 5, 2015·The FEBS Journal·Michaela Mrschtik, Kevin M Ryan
Dec 17, 2015·Cancer Research·Ruth Perets, Ronny Drapkin
Jan 1, 2016·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Daiki SekoYusuke Ono
Jan 31, 2016·Endocrine-related Cancer·Mírian RomittiAna Luiza Maia
May 10, 2016·The Journal of Clinical Investigation·Daniela Di GirolamoMonica Dentice
Sep 21, 2017·Endocrine-related Cancer·Iuri Martin GoemannAna Luiza Maia
Oct 25, 2017·Nature Communications·S Intidhar Labidi-GalyVictor E Velculescu
Jul 2, 2018·Cell Systems·Lukas Bahati TannerJoshua D Rabinowitz
Nov 8, 2018·Endocrine-related Cancer·Iuri Martin GoemannAna Luiza Maia
Jun 5, 2019·Nature Reviews. Endocrinology·Cristina LuongoDomenico Salvatore
Jun 5, 2020·Journal of Clinical Medicine·Marco ColellaConcetta Ambrosino

❮ Previous
Next ❯

Citations

Feb 5, 2021·Endocrinology·Annarita NappiDomenico Salvatore
Jun 3, 2021·Cancers·Gabriella SchieraItalia Di Liegro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.